Lataa...
C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...
Tallennettuna:
| Julkaisussa: | PLoS One |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Library of Science
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7755182/ https://ncbi.nlm.nih.gov/pubmed/33351844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0244370 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|